Updated: Egetis receives SEK 5.3 billion takeover bid from US company
US-based ANI Pharmaceuticals has made a SEK 5.3 billion takeover bid for Swedish Egetis Therapeutics. Chairman Mats Blom tells Life Science Focus why the board decided to consider a sale, despite the company's ambitions to grow independently.
This article has been updated with comments from Egetis chairman Mats Blom.
Swedish biotech company Egetis has had an eventful autumn. In late September, its drug Emcitate received FDA approval for the rare genetic disorder MCT8 deficiency, and this week the company entered into an agreement to sell its Priority Review Voucher (PRV) for $190 million.
BREAKING